Find Nebicina manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 49842-07-1, Tobramycin sulphate, Nebcin, Tobramycinsulfate, 79645-27-5, Mls000069826
Molecular Formula
C18H39N5O13S
Molecular Weight
565.6  g/mol
InChI Key
ZEUUPKVZFKBXPW-TWDWGCDDSA-N

Nebicina
An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.
1 2D Structure

Nebicina

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid
2.1.2 InChI
InChI=1S/C18H37N5O9.H2O4S/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18;1-5(2,3)4/h5-18,24-28H,1-4,19-23H2;(H2,1,2,3,4)/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+;/m0./s1
2.1.3 InChI Key
ZEUUPKVZFKBXPW-TWDWGCDDSA-N
2.1.4 Canonical SMILES
C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(CC(C(O3)CN)O)N)N.OS(=O)(=O)O
2.1.5 Isomeric SMILES
C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N.OS(=O)(=O)O
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Brulamycin

2. Nebcin

3. Nebicin

4. Nebramycin Factor 6

5. Obracin

6. Sulfate, Tobramycin

7. Tobracin

8. Tobramycin

2.2.2 Depositor-Supplied Synonyms

1. 49842-07-1

2. Tobramycin Sulphate

3. Nebcin

4. Tobramycinsulfate

5. 79645-27-5

6. Mls000069826

7. Smr000058891

8. Dartobcin

9. Nebcine

10. Tobraneg

11. Tobrasix

12. (2s,3r,4s,5s,6r)-4-amino-2-{[(1s,2s,3r,4s,6r)-4,6-diamino-3-{[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol Sulfate

13. Opera_id_1050

14. Schembl2837

15. Chembl1200780

16. Hms2230j04

17. Mfcd00133864

18. Akos025310614

19. 842t071

20. A923784

21. Tobramycin Sulfate Salt, Aminoglycoside Antibiotic

22. Q-201838

23. 2-ethoxy-5-[(morpholine-4-carbonyl)-amino]-benzenesulfonylchloride

24. (2s,3r,4s,5s,6r)-4-amino-2-(((1s,2s,3r,4s,6r)-4,6-diamino-3-(((2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2h-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,5-diol Sulfate

25. (2s,3r,4s,5s,6r)-4-amino-2-((1s,2s,3r,4s,6r)-4,6-diamino-3-((2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2h-pyran-2-yloxy)-2-hydroxycyclohexyloxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,5-diol Sulfate

26. (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol,sulfuric Acid

2.3 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 565.6 g/mol
Molecular Formula C18H39N5O13S
Hydrogen Bond Donor Count12
Hydrogen Bond Acceptor Count18
Rotatable Bond Count6
Exact Mass565.22650749 g/mol
Monoisotopic Mass565.22650749 g/mol
Topological Polar Surface Area351 Ų
Heavy Atom Count37
Formal Charge0
Complexity691
Isotope Atom Count0
Defined Atom Stereocenter Count14
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 3  
Drug NameTOBRAMYCIN SULFATE
Active IngredientTOBRAMYCIN SULFATE
CompanyAKORN (Application Number: A205179); BAXTER HLTHCARE CORP (Application Number: A206965); FRESENIUS KABI USA (Application Number: A065122); FRESENIUS KABI USA (Application Number: N050789); HOSPIRA (Application Number: A063111); HOSPIRA (Application Number: A063112); MYLAN LABS LTD (Application Number: A065407); TEVA PHARMS USA (Application Number: A063100); WEST-WARD PHARMS INT (Application Number: A063117); X GEN PHARMS (Application Number: A065013); XELLIA PHARMS APS (Application Number: A205685)

2 of 3  
Drug NameTOBRAMYCIN SULFATE (PHARMACY BULK)
Active IngredientTOBRAMYCIN SULFATE
CompanyFRESENIUS KABI USA (Application Number: A065120)

3 of 3  
Drug NameTOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Active IngredientTOBRAMYCIN SULFATE
CompanyHOSPIRA (Application Number: A063081)

5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Aminoglycosides [CS]; Aminoglycoside Antibacterial [EPC]

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty